![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ellison D. Suthoff, Mac Bonafede, Brendan Limone, Lasair O’Callaghan, Gregory S. Sawicki & Jeffrey S. Wagener. (2016) Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Journal of Medical Economics 19:9, pages 845-851.
Read now
Read now
Xavier Nogues, Maria Luz Rentero & Alicia López Rodríguez. (2014) Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide. Current Medical Research and Opinion 30:2, pages 287-296.
Read now
Read now
Robin K Dore. (2013) Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis. Patient Preference and Adherence 7, pages 435-446.
Read now
Read now
A. Migliore, S. Broccoli, U. Massafra, E. Bizzi & B. Frediani. (2012) Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis. Current Medical Research and Opinion 28:3, pages 467-473.
Read now
Read now
V. Ziller, K. Wetzel, I. Kyvernitakis, B. Seker-Pektas & P. Hadji. (2011) Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 14:2, pages 228-235.
Read now
Read now
Véronique Rabenda & Jean-Yves Reginster. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 677-689.
Read now
Read now
Articles from other publishers (24)
Hiroyuki Tsuchie, Hidekazu Abe, Norimitsu Masutani & Naohisa Miyakoshi. (2023) Comparison of the Continuation Rate of Twice-Weekly and Weekly Teriparatide Administration in a Rural Area. The Tohoku Journal of Experimental Medicine 260:2, pages 119-126.
Crossref
Crossref
Mir Sadat-Ali, Abdallah Al-Omran, Khalid AlTabash, Dakheel A. AlDakheel, Salma Elansassy, Tarek Hegazi & Mona Al Muhaish. (2022) Effects of Teriparatide on Bone Mineral Density and Prevention of Fragility Fractures in Saudi Arabian Subjects with Osteoporosis: A Two-Year Clinical Study from a Single Center. International Journal of Clinical Practice 2022, pages 1-5.
Crossref
Crossref
Ryo Fujita, Tsutomu Endo, Masahiko Takahata, Kentaro Haraya, Hisataka Suzuki, Itaru Oda, Masahiro Kanayama, Tsuyoshi Asano, Keiichi Shigenobu, Akira Iwata, Katsuhisa Yamada, Hirohito Takeuchi, Hisanori Ohura, Daisuke Yoneoka & Norimasa Iwasaki. (2022) Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis. Journal of Bone and Mineral Metabolism 40:5, pages 782-789.
Crossref
Crossref
Anthony Delbar, Arnaud Pflimlin, Isabelle Delabrière, Camille Ternynck, Christophe Chantelot, François Puisieux, Bernard Cortet & Julien Paccou. (2021) Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service. Bone 144, pages 115838.
Crossref
Crossref
Deborah T. Gold. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1695
1707
.
Hiroyuki Tsuchie, Naohisa Miyakoshi, Yuji Kasukawa, Hidekazu Abe, Norimitsu Masutani & Yoichi Shimada. (2019) Factors affecting continuation of weekly teriparatide administration in rural areas. Journal of Bone and Mineral Metabolism 38:2, pages 248-253.
Crossref
Crossref
M.A. van Maren, C.E. Wyers, J.H.M. Driessen, J.V. Visser, F. de Vries, K. van de Wijdeven, S. Gevers, W.F. Lems, M.H. Emmelot-Vonk & J.P.W. van den Bergh. (2019) Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporosis International 30:9, pages 1837-1844.
Crossref
Crossref
Nicolas Taisne, Marie-Amélie Mignot, Isabelle Legroux, Bernard Cortet & Julien Paccou. (2019) Persistance et tolérance du tériparatide dans l’ostéoporose : résultats d’une étude observationnelle dite de « vraie vie ». Revue du Rhumatisme 86:2, pages 209-210.
Crossref
Crossref
Stuart L. Silverman, E. Siris, D. Belazi, C. Recknor, A. Papaioannou, J. P. Brown, D. T. Gold, E. M. Lewiecki, G. Quinn, A. Balasubramanian, S. Yue, B. Stolshek & D. L. Kendler. (2018) Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Archives of Osteoporosis 13:1.
Crossref
Crossref
Tomoko Usui, Masaru Funagoshi, Kahori Seto, Kazuki Ide, Shiro Tanaka & Koji Kawakami. (2018) Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis. Archives of Osteoporosis 13:1.
Crossref
Crossref
C. T. Yeam, S. Chia, H. C. C. Tan, Y. H. Kwan, W. Fong & J. J. B. Seng. (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis International 29:12, pages 2623-2637.
Crossref
Crossref
Nicolas Taisne, Marie-Amélie Mignot, Isabelle Legroux, Bernard Cortet & Julien Paccou. (2018) Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice. Joint Bone Spine 85:5, pages 641-642.
Crossref
Crossref
C. Reyes, C. Tebe, D. Martinez-Laguna, M. S. Ali, A. Soria-Castro, C. Carbonell & D. Prieto-Alhambra. (2017) One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporosis International 28:10, pages 2997-3004.
Crossref
Crossref
Alona Eliasaf, Alina Amitai, Mira Maram Edry, Shimona Yosselson Superstine & Pnina Rotman Pikielny. (2016) Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday. The Journal of Clinical Pharmacology 56:11, pages 1416-1422.
Crossref
Crossref
L. Jacob, M. Dreher, K. Kostev & P. Hadji. (2015) Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporosis International 27:3, pages 963-969.
Crossref
Crossref
Anne-Luise Thorsteinsson, Peter Vestergaard & Pia Eiken. (2015) Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study. Archives of Osteoporosis 10:1.
Crossref
Crossref
Lung-I Cheng, Emily Durden, Brendan Limone, Larry Radbill, Paul L. Juneau, Leslie Spangler, Faisal M. Mirza & Bradley S. Stolshek. (2015) Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States. Journal of Managed Care & Specialty Pharmacy 21:9, pages 824-833.
Crossref
Crossref
M. M. Bonafede, N. Shi, A. G. Bower, R. L. Barron, A. Grauer & D. B. Chandler. (2015) Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporosis International 26:3, pages 1203-1212.
Crossref
Crossref
T Requena, A Ais, M Yébenes, M A Casado & M Rueda. (2014) Persistence with oral antiviral therapy in previously untreated patients with chronic hepatitis B in Spain: the EUPTHEA study. European Journal of Hospital Pharmacy 21:6, pages 344-349.
Crossref
Crossref
I. Kyvernitakis, K. Kostev, A. Kurth, U. S. Albert & P. Hadji. (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporosis International 25:12, pages 2721-2728.
Crossref
Crossref
Ikuko Tanaka, Masayo Sato, Tomoko Sugihara, Douglas E. Faries, Shuko Nojiri, Peita Graham-Clarke, Jennifer A. Flynn & Russel T. Burge. (2013) Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study. Journal of Osteoporosis 2013, pages 1-8.
Crossref
Crossref
P. Hadji, V. Ziller, D. Gamerdinger, W. Spieler, K. Articus, M. Baier, R. Moericke & P. H. Kann. (2011) Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporosis International 23:7, pages 2043-2051.
Crossref
Crossref
Sibylle P. Hämmerle, Linda Mindeholm, Aino Launonen, Beate Kiese, Rolf Loeffler, Evita Harfst, Moise Azria, Michel Arnold & Markus R. John. (2012) The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 50:4, pages 965-973.
Crossref
Crossref
Cristina Tamone, Gianfranco Fonte, Anna Panico, Pia Anna Molinatti, Patrizia D’Amelio & Giovanni Carlo Isaia. (2012) Impact of a Phone Follow-Up Program on Persistence with Teriparatide or PTH(1–84) Treatment. Calcified Tissue International 90:4, pages 272-278.
Crossref
Crossref